NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS FROM THE MEASURE 2, 3 AND 4 PHASE 3 TRIALS

被引：0
|
作者：
Dougados, M. [1 ]
Kiltz, U. [2 ,3 ]
Kivitz, A. [4 ]
Pavelka, K. [5 ]
Rohrer, S. [5 ]
Mccreddin, S. [7 ]
Quebe-Fehling, E. [6 ]
Porter, B. [8 ]
Talloczy, Z. [8 ]
机构：
[1] Univ Paris, Dept Rheumatol, Hop Cochin, Paris, France
[2] Rheumazentrum Ruhrgebiet, Herne, Germany
[3] Ruhr Univ, Bochum, Germany
[4] Altoona Ctr Clin Res, Duncansville, PA USA
[5] Inst Rheumatol, Dept Rheumatol, Prague, Czech Republic
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Ireland Ltd, Dublin, Ireland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.824
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0374
引用
收藏
页码：415 / 416
页数：2
相关论文
共 50 条
  • [41] Secukinumab 150 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan J.
    Blanco, Ricardo
    Cohen, Martin
    Delicha, Evie Maria
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [42] THE EFFECT OF ANTI-INFLAMMATORY THERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS ACCORDING TO THE RESULTS OF A THREE-YEAR OB- SERVATION
    Raskina, T.
    Pirogova, O.
    Malyshenko, O.
    Fanaskov, V.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S279 - S280
  • [43] Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
    Baraliakos, Xenofon
    Schiff, Michael
    Pavelka, Karel
    Martin, Ruvie
    Porter, Brian
    Gaillez, Corine
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [44] Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis - Detailed Results from a Phase 3 Trial
    Baraliakos, Xenofon
    Braun, Juergen
    Widmer, Albert
    Das Gupta, Ayan
    Readie, Aimee
    Porter, Brian
    Gaillez, Corine
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [45] Secukinumab sustains individual clinical responses over time in patients with active ankylosing spondylitis: 2-year results from a phase 3 randomized placebo-controlled trial
    Bannert, B.
    Baraliakos, X.
    Schiff, M.
    Pavelka, K.
    Martin, R.
    Gaillez, C.
    SWISS MEDICAL WEEKLY, 2017, 147 : 8S - 9S
  • [46] Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
    Kivitz, Alan J.
    Pavelka, Karel
    Dokoupilova, Eva
    Blanco, Ricardo
    Maradiaga, Marco
    Tahir, Hasan
    Wang, Yi
    Porter, Brian
    Stefanska, Anna
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [47] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 3-YEAR RESULTS FROM PHASE III TRIAL, MEASURE 2
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A. J.
    Blanco, R.
    Cohen, M.
    Delicha, E. M.
    Rohrer, S.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 345 - 345
  • [48] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: THREE-YEAR RESULTS FROM PHASE 3 TRIAL, MEASURE 2
    Tahir, Hasan
    Marzo-Ortega, Helena
    Legerton, Clarence W.
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Ricardo
    Cohen, Martin
    Delicha, Evie Maria
    Rohrer, Susanne
    Richards, Hanno B.
    RHEUMATOLOGY, 2018, 57
  • [49] Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
    Baraliakos, Xenofon
    Deodhar, Atul A.
    Braun, Juergen
    Baeten, Dominique
    Dougados, Maxime
    Sieper, Joachim
    Emery, Paul
    Readie, Aimee
    Martin, Ruvie
    Mpofu, Shephard
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [50] Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies
    Wei, James C. -C.
    Baeten, Dominique
    Sieper, Joachim
    Deodhar, Atul
    Bhosekar, Vaishali
    Martin, Ruvie
    Porter, Brian
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (05) : 589 - 596
12345